Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the first data from the Phase ...